SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups

The University of Texas System (UT)

Status: Completed

Conditions: Smoking Cessation

Treatments: Behavioral: SmokefreeSGM; Behavioral: SmokefreeTXT

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05645354

K22CA237639 (U.S. NIH Grant/Contract)

HSC-SPH-22-0717

Details and patient eligibility

About

The purpose of this study is to test the feasibility and acceptability of Smokefree Sexual and Gender Minority (SGM), an SGM-tailored version of the SmokefreeTXT text messaging program

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Self-identify as an LGBTQ+ individual
• Currently live in the United States
• Have smoked at least 100 cigarettes in their lifetime, smoke every day, and smoke greater than or equal to 5 cigarettes a day
• Are willing to quit smoking in the next 15 days
• Have a cell phone number with an unlimited short message service (SMS) plan
• Have a positive cotinine saliva test to indicate their smoking status

Exclusion criteria

• Have a prepaid cell phone plan (pay-as-you-go plan)
• Have a cell phone number that does not work and/or is registered to someone else
• Have inadequate equipment/devices (i.e., webcam, speakers, mic) for participating in telehealth sessions via Microsoft Teams, Webex, or Zoom AND cannot meet in-person
• Pregnant or breastfeeding persons (nicotine patches are not generally recommended to this groups since nicotine can affect fetal and neonatal brain development)
• Contraindication for nicotine patches. Absolute contraindications include: severe eczema or serious skin conditions, allergy to nicotine patches, pregnancy, breastfeeding, heart attack in the past 2 months, ongoing angina, peptic ulcer disease, arrhythmia, or uncontrolled blood pressure. Potential contraindications include: stroke in the past 6 months, insulin therapy, and a current diagnosis of liver, kidney, or heart disease. Study participants reporting a potential contraindication will require approval from their primary care provider and/or other treating physician (e.g., psychiatrist) to use nicotine patches. If the request is denied or not returned in 2 weeks, potential study participants will be excluded from the study.
• Current use of tobacco cessation medications
• Enrollment in another smoking cessation study
• Non-English speakers

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

SmokefreeSGM

Experimental group

Treatment:

Behavioral: SmokefreeSGM

SmokefreeTXT

Active Comparator group

Treatment:

Behavioral: SmokefreeTXT